8 results match your criteria: "University of Florence Viale G[Affiliation]"
Cancer Chemother Pharmacol
June 2022
Department of Experimental and Clinical Biomedical Sciences, Mario Serio" University of Florence Viale G.B. Morgagni 50, 50134, Florence, Italy.
Purpose: Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Standard treatment consists of tumor debulking surgery followed by platinum and paclitaxel chemotherapy; yet, despite the initial response, about 70-75% of patients develop resistance to chemotherapy. Gold compounds represent a family of very promising anticancer drugs.
View Article and Find Full Text PDFCancers (Basel)
July 2020
Department of Experimental and Clinical Biomedical Sciences School of Health Sciences, University of Florence-Viale G.B. Morgagni, 50-50134 Florence, Italy.
Targeted and immune therapies have unquestionably improved the prognosis of melanoma patients. However the treatment of this neoplasm still requires approaches with a higher therapeutic index, in order to reduce shortcomings related to toxic effects and aspecific targeting. This means developing therapeutic tools derived with high affinity molecules for tumor components differentially expressed in melanoma cells with respect to their normal counterpart.
View Article and Find Full Text PDFCurr Diabetes Rev
September 2012
Department of Anatomy, Histology & Forensic Medicine, University of Florence viale G.Pieraccini, 6. I-50139, Florence, Italy.
Until recently, relaxin and insulin were grouped into the same hormone superfamily because of substantial biochemical homologies. This notion has then changed with the understanding that insulin and relaxin are ligands for different receptors and signal transduction systems, namely, tyrosine kinase and G-protein-coupled receptors respectively. As a matter of fact, relaxin does not mimic the metabolic effects of insulin.
View Article and Find Full Text PDFF1000 Med Rep
February 2010
Division of Hematology, Department of Critical Care, University of Florence Viale G Morgagni 85, 50134 Firenze Italy.
The Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) have recently been the focus of tremendous advances in basic knowledge of disease pathophysiology following the recognition of mutations in JAK2 and MPL. These discoveries also led to refinement of the criteria employed for diagnosis. The prognostic roles of the JAK2 V617F mutation and of leukocytosis as independent risk factors for thrombosis, which represents the leading cause of death in patients with polycythemia vera and essential thrombocythemia, are supported by retrospective studies.
View Article and Find Full Text PDFBMC Cancer
September 2010
Department of Experimental Pathology and Oncology, University of Florence Viale G,B, Morgagni, Florence - Italy.
Background: Treatment strategies for Retinoblastoma (RB), the most common primary intraocular tumor in children, have evolved over the past few decades and chemoreduction is currently the most popular treatment strategy. Despite success, systemic chemotherapeutic treatment has relevant toxicity, especially in the pediatric population. Antiangiogenic therapy has thus been proposed as a valuable alternative for pediatric malignancies, in particolar RB.
View Article and Find Full Text PDFJ Pharmacol Exp Ther
February 2008
Dept. Preclinical and Clinical Pharmacology, University of Florence. Viale G. Pieraccini 6, I-50139 Florence, Italy.
Although mechanisms involved in the pathogenesis of asthma remain unclear, roles for oxidative/nitrosative stress, epithelial cell apoptosis, and airway inflammation have been documented. Ceramide is a sphingolipid with potent proinflammatory and proapoptotic properties. This study aimed at determining whether increased formation of ceramide contributes to the development of airway inflammation and hyper-responsiveness, using a well characterized in vivo model of allergic asthmatic response and airway inflammation in ovalbumin-sensitized guinea pigs.
View Article and Find Full Text PDFPain
November 1993
Pain Center, University of Florence Viale G.B. Morgagni 85 50134 Florence, Italy.